Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexuclue Tab. in Prevention of NSAIDs-induced Peptic Ulcer
NCT07533266Phase 4Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fexuprazan in peptic ulcer disease (PUD), sponsored by Daewoong Pharmaceutical. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
fexuprazan
03
Conditions
peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT07533266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07533266.